Roisin Connolly, MD, University College Cork, Cork, Ireland, provides a horizon scan of breast cancer care, including an increased focus on de-escalation strategies as evaluated in the ongoing CompassHER2-pCR study (NCT04266249), a Phase II study delineating how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery after pre-operative chemotherapy and HER2-targeted therapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
